|Bid||0.00 x 100000|
|Ask||0.00 x 100000|
|Day's Range||21.31 - 21.44|
|52 Week Range||9.45 - 24.51|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_05082018.pdf PRINCIPAUX INDICATEURS À L’AGENDA 08:15 Mises en ...
From a headline standpoint, Allergan plc (NYSE:AGN) stock does look attractive at the moment. A steady pullback has seen Allergan stock fall about 35% from late July highs and Allergan has dropped by half from 2015 levels. A sub-10x forward EPS multiple is notably cheaper than those assigned to rivals like Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK).
For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical or early production stage firms.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) still has its share of detractors. Late last month Valeant stock came out with its quarterly confessional, which featured an improving and profitable bottom-line of 98-cents-per-share.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock took a hit today following the release of its earnings report for the fourth quarter of 2017. The big blow to VRX stock today was the company’s revenue of $2.16 billion for the fourth quarter of the year. It also came in below Wall Street’s revenue estimate of $2.18 billion for the quarter.
It shows revenues of $222.8 million, nearly double the previous year’s $130 million, and a gross profit of $121 million. During my reporting career, I have seen several Canadian companies rise, and then fall, on their own hype.